Takeda Pharmaceutical Co. $TAK Shares Sold by Tsfg LLC

Tsfg LLC lowered its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 29.0% in the second quarter, Holdings Channel reports. The firm owned 16,019 shares of the company’s stock after selling 6,529 shares during the period. Tsfg LLC’s holdings in Takeda Pharmaceutical were worth $248,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Takeda Pharmaceutical by 5.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after buying an additional 1,098 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in Takeda Pharmaceutical during the first quarter worth about $262,000. Envestnet Portfolio Solutions Inc. grew its stake in Takeda Pharmaceutical by 29.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 15,112 shares of the company’s stock valued at $234,000 after acquiring an additional 3,410 shares in the last quarter. Finally, Cerity Partners LLC raised its holdings in Takeda Pharmaceutical by 81.7% in the 1st quarter. Cerity Partners LLC now owns 159,285 shares of the company’s stock valued at $2,369,000 after acquiring an additional 71,634 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Up 1.5%

TAK opened at $13.44 on Monday. The stock has a market capitalization of $42.75 billion, a PE ratio of 44.78 and a beta of 0.21. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The business’s 50 day moving average price is $14.59 and its 200 day moving average price is $14.73.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.32 billion for the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TAK. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. Weiss Ratings reiterated a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Hold”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.